DGRC
AddressSinamangal-9, Kathmandu, Nepal
Call us01-4116637, 9808250408

EGFR Gene Mutation Testing

EGFR is a short name for the epidermal growth factor receptor gene. This test detects mutations in the EGFR gene in cancer tissue. This information is useful in guiding treatment of non-small cell lung cancer. The EGFR gene codes for a specialized protein called a receptor located on the surface of cells. Receptors recognize and bind to other substances, and the binding typically has a specific effect on the cells. EGFR is one of a group of receptors called receptor tyrosine kinases that help regulate cell growth, division, survival, and death. This regulation is a very complex process involving the activation of a series of signals along various pathways. Receptor tyrosine kinases like EGFR transmit signals from the surface of the cell to within the cell. In normal cells, the binding of epidermal growth factor to its receptor on the cell surface is an important signal that promotes cell proliferation. Certain mutations called "activating mutations" in the EGFR gene can result in excessive signaling for growth and uncontrolled proliferation of cancer cells.
Treatment that targets EGFR is a valuable molecular approach in cancer therapy. Examples of EGFR-targeted therapy include drugs such as gefitonib and erlotinib, which are small molecules called tyrosine kinase inhibitors (TKIs) that enter cancer cells and impede signaling. These drugs have been shown to be useful in treating non-small cell lung cancer (NSCLC). Studies have shown that targeted therapy with these TKIs will only work in a subset of NSCLC with specific activating mutations in the EGFR gene. If an activating mutation is present, as detected with an EGFR mutation test, then the drugs directed against EGFR are much more likely to be effective and the patient should benefit from targeted therapy.

EGFR Mutation Test

EGFR mutation testing is ordered when an individual has been diagnosed with non-small cell lung cancer, especially adenocarcinoma, and the person is a candidate for treatment with an EGFR inhibitor. Currently, if EGFR mutation testing is performed as part of a series of tests, KRAS mutation testing is usually done first. If the tumor is negative for KRAS, then EGFR mutation testing may be done, and if that is negative, then a test for ALK mutation may be performed.

What does the test result mean?
If EGFR mutation testing indicates that an EGFR-activating mutation is present in cancer tissue, then the affected individual is likely to respond to therapy that targets EGFR. If the tumor is negative for an EGFR mutation, then the person is not likely to respond to a tyrosine kinase inhibitor. ALK mutation testing may then used to determine whether the person's tumor would be likely to respond to an ALK kinase inhibitor.
If KRAS mutation testing is performed and indicates that the tumor lacks a KRAS mutation, then the affected person is likely to respond to an anti-EGFR drug therapy (tyrosine kinase inhibitor, TKI). If the tumor has a KRAS mutation, then it is unlikely to harbor an EGFR mutation or respond to anti-EGFR drug therapy. (In non-small cell lung cancer, EGFR and KRAS mutations are mutually exclusive—the tumor can have one or the other but not both.)
A person could have a negative test result if the tumor tissue sample is insufficient and/or when there are insufficient cancer cells present that contain the mutation. Additionally, there may be EGFR mutations present that are not detected by this testing.

**Note: EGFR mutation testing is not available in every laboratory. If a health practitioner sends a sample to a reference laboratory, the results may take a week before they are available.

In Nepal Decode Genomics and Research Center has been doing this testing at its Molecular Diagnostic Laboratory situated at Sinamangal.

Image placeholder

George Washington

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Ducimus itaque, autem necessitatibus voluptate quod mollitia delectus aut, sunt placeat nam vero culpa sapiente consectetur similique, inventore eos fugit cupiditate numquam!

Leave a comment